Literature DB >> 15667428

Structural and functional models of depression: from sub-types to substrates.

G S Malhi1, G B Parker, J Greenwood.   

Abstract

OBJECTIVE: To present a functional model of depression facilitating research and clinical understanding.
METHOD: The authors conducted a systematic literature search and reviewed articles pertaining to the neurochemistry and pathophysiology of depressive disorders, focusing on the contribution made by the principal monoamines to three differing depressive structural sub-types (i.e. psychotic, melancholic and non-melancholic).
RESULTS: We suggest that the three structural depressive subtypes appear functionally underpinned by differential contributions of serotonergic, noradrenergic and dopaminergic neurotransmitters, so influencing phenotypic distinction (our structural model) and allowing an aetiological model to be derived with treatment specificity implications.
CONCLUSION: The functional model logically iterates with the structural model of depression and provides a useful framework for conceptualizing the depressive disorders. This model provides a logic for distinguishing between principal depressive subtypes, pursuing their functional underpinnings and explaining treatment differential effects across the three sub-types.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667428     DOI: 10.1111/j.1600-0447.2004.00475.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  17 in total

1.  Does psychomotor retardation define a clinically relevant phenotype of unipolar depression?

Authors:  S Calugi; G B Cassano; A Litta; P Rucci; A Benvenuti; M Miniati; L Lattanzi; V Mantua; V Lombardi; A Fagiolini; E Frank
Journal:  J Affect Disord       Date:  2010-09-15       Impact factor: 4.839

2.  Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter and Stress Hormone Systems.

Authors:  Mariam B Camacho; Warut D Vijitbenjaronk; Thomas J Anastasio
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

3.  Major depressive disorder with melancholia displays robust alterations in resting state heart rate and its variability: implications for future morbidity and mortality.

Authors:  Andrew H Kemp; Daniel S Quintana; Candice R Quinn; Patrick Hopkinson; Anthony W F Harris
Journal:  Front Psychol       Date:  2014-11-27

4.  The development of valid subtypes for depression in primary care settings: a preliminary study using an explanatory model approach.

Authors:  Alison Karasz
Journal:  J Nerv Ment Dis       Date:  2008-04       Impact factor: 2.254

Review 5.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

6.  Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.

Authors:  R Kaddurah-Daouk; S H Boyle; W Matson; S Sharma; S Matson; H Zhu; M B Bogdanov; E Churchill; R R Krishnan; A J Rush; E Pickering; M Delnomdedieu
Journal:  Transl Psychiatry       Date:  2011       Impact factor: 6.222

7.  Do antidepressants cure or create abnormal brain states?

Authors:  Joanna Moncrieff; David Cohen
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

Review 8.  The functional anatomy of psychomotor disturbances in major depressive disorder.

Authors:  Benny Liberg; Christoffer Rahm
Journal:  Front Psychiatry       Date:  2015-03-10       Impact factor: 4.157

9.  How Can We Predict Treatment Outcome for Depression?

Authors:  Martin Walter; Anton Lord
Journal:  EBioMedicine       Date:  2014-12-18       Impact factor: 8.143

10.  Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.

Authors:  R Kaddurah-Daouk; M B Bogdanov; W R Wikoff; H Zhu; S H Boyle; E Churchill; Z Wang; A J Rush; R R Krishnan; E Pickering; M Delnomdedieu; O Fiehn
Journal:  Transl Psychiatry       Date:  2013-01-22       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.